Journal Logo

You can read the full text of this article if you:

Ovid Member Institutional Access
ORIGINAL ARTICLES: Clinical research

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

Garcia, Miki Shirakawaa; Ono, Yokoa; Martinez, Steve R.b; Chen, Steven L.b; Goodarzi, Heidia; Phan, Tiffanya; Wehrli, Lisa N.a; Miyamura, Yoshinoria; Fung, Maxwell A.a; Maverakis, Emanuala,c

Author Information
doi: 10.1097/CMR.0b013e328345e95e

Abstract

Erratum

The authors of the article ‘Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream’ that was published in the June issue this year would like to make readers aware that the following sentence that were published in the article should be corrected as shown below:

In the abstract the sentence ‘Additional studies are needed to determine whether this therapy is associated with a survival benefit.’ should read ‘Future studies are needed to determine whether this therapy is associated with survival benefit’.

In the first sentence of the discussion ‘Although this study is limited to just three patients...’ (p240) should be changed to ‘Although this report is limited to just three patients ...’.

In the discussion paragraph beginning with ‘With respect to this study, it is important to note that a tumor-specific systemic immune ...’ (p242), the sentence should have read ‘With respect to this report, it is important to note that a tumor-specific systemic immune ...’.

In the last paragraph of the Discussion the sentence ‘We are aware of several other limitations to this study’. (p243) should have read ‘We are aware of several other limitations to this report ’.

The authors apologise for these errors.

Melanoma Research. 23(1):83, February 2013.

© 2011 Lippincott Williams & Wilkins, Inc.